Ibodutant
Ibodutant is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target substance-K receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
5 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | 2 | 3 | — | — | 5 |
| Syndrome | D013577 | — | — | — | 2 | 3 | — | — | 5 |
| Diarrhea | D003967 | — | R19.7 | — | 1 | 3 | — | — | 4 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ibodutant |
| INN | ibodutant |
| Description | Ibodutant was a candidate drug for irritable bowel syndrome diarrhea, developed by The Menarini Group. As of March 2015, it underwent a multicentre double blind efficacy clinical study. Ibodutant selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations. A phase 2 trial in Europe (the IRIS-2 trial) completed in May 2012 with positive results. A 52-week phase 3 study was terminated as of 2015 because of low response and negative results of study NAK-06.
|
| Classification | Small molecule |
| Drug class | tachykinin (neurokinin) receptor antagonists: NK2 receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc2cc(C(=O)NC3(C(=O)N[C@H](Cc4ccccc4)C(=O)NCC4CCN(CC5CCOCC5)CC4)CCCC3)sc2c1 |
Identifiers
| PDB | — |
| CAS-ID | 1714146-59-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL266125 |
| ChEBI ID | — |
| PubChem CID | 11527495 |
| DrugBank | — |
| UNII ID | 1H7RSQ28BJ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
TACR2
TACR2
Organism
Homo sapiens
Gene name
TACR2
Gene synonyms
NK2R, NKNAR, TAC2R
NCBI Gene ID
Protein name
substance-K receptor
Protein synonyms
neurokinin 2 receptor, Neurokinin A receptor, neurokinin B receptor, NK-2 receptor, NK-2R, seven transmembrane helix receptor, Tachykinin receptor 2
Uniprot ID
Mouse ortholog
Tacr2 (21337)
substance-K receptor (P30549)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 49 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use